Abstract
ObjectivesTo evaluate the infection risk and long-term safety of prolonged peripheral CD19+ B cell depletion (BCD) following rituximab (RTX) treatment in RA clinical trials.MethodsSubgroups of patients (pts) with peripheral BCD...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
